A Phase 1 Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies

Trial Profile

A Phase 1 Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs BLU 285 (Primary)
  • Indications Systemic mastocytosis
  • Focus Adverse reactions; Proof of concept
  • Sponsors Blueprint Medicines
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 09 Mar 2017 According to a Blueprint Medicines Corporation media release, enrollment in the dose escalation portion of this clinical trial is ongoing and company anticipates providing updated data from this clinical trial in 2017.
    • 06 Dec 2016 Results (n=6, data cut off: 21 Jul 2016) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top